**S3 Table. Association of Drug Susceptibility with Selected Clinical Manifestations and Treatment Outcomes Among Patients with Pulmonary TB by Multivariate Analyses. Orizaba, Veracruz, 1995-1998.**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Variable | Delay in conversion >60 days | Recurrence HR | Death due to any cause | Death due to TB (All patients)a | Death due to TB (HIV negative patients) a |
|  | (95% CI) b | (95% CI) c | (95% CI) c | (95% CI) c | (95% CI) c |
|   | n=226 | n=220 | n= 210 | n= 2010 | n= 206 |
| Mono-resistant to isoniazid (vs pan-susceptible) | 2.23 | 1.07 | 1.24 | 4.87 | 5.58 |
|  | (0.89-5.57) | (0.24-4.74) | (0.55-2.81) | (0.73-32.43) | (0.85-36.77) |
| Male | 1.29 | 1.02 | 0.61 | 0.72 | 1.49 |
|  | (0.65-2.58) | (0.24-4.38) | (0.28-1.36) | (0.05-10.11) | (0.23-9.50) |
| Age | 1.00 | 1.00 | 1.04 | 1.03 | 1.03 |
|  | (0.98-1.02) | (0.97-1.04) | (1.02-1.06)f | (0.97-1.10) | (0.97-1.10) |
| >10 drinks a week | 0.31 | 2.77 | 2.69 | 2.80 | --- |
|  | (0.14-0.71)e | (0.75-10.30) | (1.23-5.87)d | (0.23-33.49) | --- |
| Knows another person with TB | --- | 1.40 | 0.87 | 2.69 | --- |
|  |  | (0.53-3.68) | (0.49-1.54) | (0.42-17.37) | --- |
| History of previous TB treatment | 0.65 | 0.99 | 1.38 | 7.47 | 6.85 |
|  | (0.26-1.64) | (0.22-4.44) | (0.70-2.71) | (1.13-49.10) d | (1.06-44.06) d |
| Diabetes Mellitus | --- | 0.88 | 1.17 | --- | --- |
|  |  | (0.25-3.06) | (0.64-2.12) |  |  |
| HIV infection | --- | 10.96 | 53.57 | 101.96 | --- |
|  |  | (1.23-97.72) d | (15.51-185.05) f | (5.28-1967.37) e | --- |
| Cavitation Cavities in chest X ray | --- | --- | 0.78 | 0.40 | 0.55 |
|  | --- | --- | (0.44-1.38) | (0.04-3.72) | (0.06-5.12) |

HIV, human immunodeficiency virus; TB, tuberculosis

a Patients who failed were compared with patients who cured or completed treatment.

b Unconditional logistic regression model.

c Cox proportional hazards model

d<0.050

e<0.010

f<0.001